Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor
November 07, 2018
Share
Anterogen Co.,Ltd. (KOSDAQ:A065660) announced a private placement of 135,85 registered convertible preferred shares at a price of KRW 73,600 per share for gross proceeds of KRW 9,999,222,400 on November 8, 2018. Korea Investment & Securities Co., Ltd., Investment Arm for 59,778 shares, Samsung Securities Co. Ltd., Investment Arm for 51,626 shares, Yen H investments securities corporation for 17,662 shares, and another investor. The preferred shares will convert into common shares of the company between November 16, 2019 and November 8, 2023. The shares were issued through a third party allotment method. The payment date of the transaction is November 15, 2018. The securities being issued are subject to a lock up period of one year. The transaction has been approved by the board of directors of the company.
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor